Sucampo Pharmaceuticals (SCMP) Upgraded by ValuEngine to “Strong-Buy”

Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

Other analysts have also issued reports about the company. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, October 17th. UBS Group reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Instinet assumed coverage on Sucampo Pharmaceuticals in a research report on Tuesday, December 19th. They issued a “buy” rating and a $43.00 price target for the company. Nomura assumed coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $43.00 price target for the company. Finally, Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 7th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $20.25.

Shares of Sucampo Pharmaceuticals (SCMP) opened at $17.98 on Friday. The stock has a market capitalization of $846.67, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 5.04 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $18.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 earnings per share. equities research analysts predict that Sucampo Pharmaceuticals will post 1.12 EPS for the current year.

In related news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.13% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of SCMP. Point72 Asset Management L.P. purchased a new position in Sucampo Pharmaceuticals during the third quarter worth about $21,989,000. Prudential Financial Inc. grew its position in Sucampo Pharmaceuticals by 871.6% during the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after buying an additional 368,090 shares in the last quarter. Gabelli Funds LLC purchased a new position in Sucampo Pharmaceuticals during the fourth quarter worth about $5,403,000. Engineers Gate Manager LP grew its position in Sucampo Pharmaceuticals by 367.5% during the fourth quarter. Engineers Gate Manager LP now owns 261,931 shares of the biopharmaceutical company’s stock worth $4,702,000 after buying an additional 205,901 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC purchased a new position in Sucampo Pharmaceuticals during the fourth quarter worth about $3,590,000. Institutional investors and hedge funds own 65.01% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/04/sucampo-pharmaceuticals-scmp-upgraded-by-valuengine-to-strong-buy.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit